MedPath

Acetylsalicylic acid as an adjuvant therapy for schizophrenia.

Completed
Registration Number
NL-OMON22886
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

1. Schizophrenia
2. Schizo-affective disorder
3. Schizofreniform disorder according to DSM-IV (for max 10 years)
4. Age 18 - 55 years
5. Stabile, min. 60 on PANSS, min 2x a score of min 4 on PANSS.

Exclusion Criteria

1. No contraindication for acetylsalicylic acid
2. No hypersensitivity to acetylsalicylic acid or pantoprazole
3. No significant somatic illness
4. No chronic use of a nonsteroidal anti-inflammatory drug (NSAID)
5. No use of corticosteroids
5. Not pregnant
6. No drugs dependency
7. Informed consent obtained.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
3-month change in positive and negative symptoms on the total PANSS score.
Secondary Outcome Measures
NameTimeMethod
3-month change in the PANSS subscales, cognitive symptoms, immunological parameters (g-interferon, IL-4, IL-6 and IL-12).
© Copyright 2025. All Rights Reserved by MedPath